Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk ...

Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare ...

The race to develop the next generation of weight loss drugs has taken an interesting new turn. In recent research, Eli Lilly ...

The maker of the weight-loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of these blockbuster ...

Robbie Williams warns GLP-1 drugs may cause vision loss. What does this mean for food & beverage innovation and natural ...

After a rapid rise, Eli Lilly needs only an 11% gain to hit $1 trillion in market value. Revenue is expected to rise 26% next ...

US accounts for 72.7% of the MSCI World Index, compared with just 2.6% for Europe’s biggest stock market, France ...

Shares of LifeMD were higher after Novo Nordisk slashed prices for its GLP-1 obesity drugs for customers who pay out of pocket. The stock rose 5.8% to $4.90 in premarket trading. LifeMD said the lower ...

Plus, semaglutide’s patent expiry across major emerging markets, including India, Brazil and China, is expected to open the field to generic manufacturers and sharply expand access.

The Trump administration struck a new deal with Eli Lilly to offer the drug maker’s weight loss drug to some Medicare ...

Trump deals with Eli Lilly and Novo Nordisk increase access to obesity drugs, providing a safe, convenient way to slim down ...